Simon Harford serves as the Chief Financial Officer (CFO) at Amicus Therapeutics Inc., a position he has held since joining the company in 2012. With a robust background in finance and biotechnology, Harford has been instrumental in guiding Amicus through significant growth and development phases. Before joining Amicus, he held the position of CFO at EUSA Pharma, where he played a key role in the company's successful acquisition and subsequent integration into Jazz Pharmaceuticals. His extensive experience in the life sciences sector also includes stints at Aventis and Pharmacia, where he honed his skills in financial strategy and corporate development. At Amicus Therapeutics, Harford has been pivotal in steering the company's financial strategy, overseeing capital-raising efforts that have supported the development and commercialization of novel therapies for rare diseases. Under his leadership, Amicus has successfully navigated the complexities of the biotech market, achieving key milestones such as the approval and launch of Galafold, a groundbreaking treatment for Fabry disease. Harford's strategic vision has also been crucial in forging partnerships and collaborations that have bolstered the company's research and development pipeline. His role extends beyond traditional CFO responsibilities, as he actively participates in shaping the company's overall business strategy and ensuring its alignment with long-term growth objectives. Harford's achievements at Amicus have been recognized within the industry, earning him a reputation as a forward-thinking leader in the biotechnology space. His ability to balance financial acumen with a deep understanding of the scientific and regulatory landscapes has been a driving force behind Amicus's success. As CFO, Harford continues to lead the company's financial operations with a focus on sustainable growth and innovation, ensuring that Amicus remains at the forefront of developing life-changing therapies for patients with rare diseases.